Charles Zhu
Stock Analyst at Guggenheim
(2.82)
# 1,924
Out of 5,090 analysts
27
Total ratings
56.52%
Success rate
23.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $9.63 | +24.61% | 4 | Oct 24, 2025 | |
| MRUS Merus | Downgrades: Market Perform | $97 | $96.14 | +0.89% | 7 | Sep 30, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $13.07 | +68.32% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $2.22 | - | 1 | Dec 13, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.37 | +775.91% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $109.60 | -48.91% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.58 | +294.27% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $38.77 | -32.94% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $35.87 | -10.79% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $26.69 | -47.55% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $9.63
Upside: +24.61%
Merus
Sep 30, 2025
Downgrades: Market Perform
Price Target: $97
Current: $96.14
Upside: +0.89%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $13.07
Upside: +68.32%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.22
Upside: -
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.37
Upside: +775.91%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $109.60
Upside: -48.91%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.58
Upside: +294.27%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $38.77
Upside: -32.94%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $35.87
Upside: -10.79%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $26.69
Upside: -47.55%